
TMDX Stock Forecast & Price Target
TMDX Analyst Ratings
Bulls say
TransMedics Group is viewed favorably because its core Organ Care System is gaining traction across liver, heart, and lung transplant markets, with 3Q26 revenue of $203M and non-GAAP EPS of $0.51 beating consensus while organic revenue growth accelerated to 35% from 21% in 2Q26. The company’s outlook is further strengthened by raised 2026 revenue guidance to $764M-$774M, expanding liver sales of $150M, and multiple regulatory and clinical catalysts, including completion of ENHANCE Part A and FDA IDE approval for ENHANCE Part B and DENOVO. Despite near-term margin pressure from growth investments, the platform’s large underpenetrated market, improving operating leverage, and potential incremental demand from CHOPS, OCS Kidney, and international expansion support a constructive long-term fundamental view.
Bears say
TransMedics Group is facing a fundamentally fragile outlook because its revenue base is concentrated in a narrow OCS platform, with limited product diversification and reliance on fewer than 100 transplant centers in the US. Adoption risk remains high as the company must displace cold storage with a novel model that still lacks a specific US reimbursement code, while reimbursement cuts, regulatory delays, or government scrutiny could materially pressure demand and estimates. Financially, the outlook is further weakened by rising fixed costs, with quarterly interest expense lifted to $7.2M from $3.6M and FY26 total interest expense raised to $28.8M, adding strain to execution.
This aggregate rating is based on analysts' research of Transmedics Group Inc and is not a guaranteed prediction by Public.com or investment advice.
TMDX Analyst Forecast & Price Prediction
Start investing in TMDX
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Transmedics Group Inc (TMDX) Forecast
TMDX Analyst Forecast & Price Prediction
Start investing in TMDX
Order type
Buy in
Order amount
Est. shares
0 shares